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Aging is like the weather: everyone talks about it, but no one seems to do anything about it. We believe this may soon 
change, as an improved understanding of the molecular and genetic pathways underlying aging suggests it is possi-
ble to therapeutically target the aging process and increase health span. This Review series focuses on fundamental 
cellular mechanisms of aging and their relationship to human disease. These pathways include telomere dysfunc-
tion in cellular senescence and induction of the senescence-associated secretory phenotype (SASP) in systemic aging, 
sirtuin family regulation of metabolism and aging-associated diseases, mitochondrial metabolism in aging, the 
mechanistic target of rapamycin (mTOR) signaling pathway and the use of mTOR inhibitors to increase longevity, 
the progressive decline of the immune system with age, and aging-associated changes to pancreatic islet β cells that 
may contribute to diabetes. Together, these articles explore pathways affecting aging and possible interventional 
targets to slow or delay the onset of age-related pathologies.
Introduction
Diverse factors, including the sharp peak in births following World 
War II (the “baby boom”), a rise in worldwide life expectancy (from 
48 years in the 1950s to a projected 76 years by 2050), and a decline 
in fertility, are contributing to a dramatic increase in the percentage 
of humans over the age of 60 years (1). Currently, approximately 800 
million people are at least 60 years old, which represents about 11% 
of the world’s population; by 2050, this is expected to increase to 
more than 2 billion people, representing 22% of the population. On 
a positive note, we can expect a longer period of work productivity 
and life experiences, in many cases stretching well beyond the age of 
60 and into the 70s and 80s. Less positive is the specter of an ever-
expanding pool of people experiencing inevitable age-related deteri-
oration in health and onset of frailty, and the impact of such a surge 
on health care systems and national economies already under severe 
duress. Despite an expectation that a greater proportion of our soci-
ety will enjoy a sustained period of “healthy aging,” aging remains a 
strong risk factor for all of our most prevalent and life-threatening 
chronic diseases, including cardiovascular disease, cancer, type 2 dia-
betes, and skeletal/muscular diseases.
In light of the profound effects of aging on human health, the 
JCI has commissioned a series of Review articles highlighting the 
fundamental cellular mechanisms of aging and their relationship 
to human diseases and conditions. The series is not intended to be 
exhaustive, but rather is focused on selected mechanisms that affect 
several aspects of aging biology. In particular, we have asked the 
authors to focus on near-term therapeutic and clinical implications 
of an enhanced understanding of aging biology.
Historical background
Classic broad symptoms of aging in mammalian species include 
increased curvature of the spine (kyphosis), reduced fertility, loss 
of hearing and eyesight, graying and loss of hair, anemia and 
immune failure, weight loss, frailty, and loss of cognition. These 
systemic changes are driven by a variety of molecular, biochemi-
cal, and metabolic alterations that occur at the cellular level. The 
field of aging research has grappled for years to develop unifying 
mechanisms to explain the broad biological effects of the aging 
process, and to identify pathways that can be targeted to delay or 
reverse it. This work is complicated by the fact that a major out-
come measure in aging research is life span, which is of course 
affected by lethal diseases such as cancer and cardiovascular dis-
ease that develop either as a consequence of or independently from 
the aging process per se. Though aging remains an inexorable fact 
of human life, this series highlights important insights that have 
been gained in the mechanistic understanding of this fundamen-
tal process (Figure 1).
Several major theories have been advanced to explain the biology 
of aging that are not mutually exclusive. The free radical theory of 
aging postulates that gradual aging-associated dysfunction of the 
mitochondrial electron transport chain results in a higher rate of 
production of superoxide and related oxygen radicals. The accu-
mulation of these radicals in turn leads to oxidative damage of 
multiple cellular elements, including structural proteins and mem-
brane lipids, hastening the overall phenotype of cellular senescence 
and functional decline. In addition, alterations in nutrient-sensing 
pathways, most notably the insulin/IGF-1 signaling pathway and 
the target of rapamycin (TOR) pathways, are thought to underlie 
the aging process. Higher activity of these pathways is promoted 
by nutrient abundance (the “anabolic state”) and is associated with 
more rapid aging for reasons that remain unclear. The senescence 
theory of aging suggests that replication-competent cells become 
exhausted and enter a permanent state of growth arrest called “cel-
lular senescence” as a result of a variety of insults including short 
telomeres and other forms of DNA damage, oxidative stress, and/
or changes in chromatin architecture. This decline in replicative 
capacity can lead to functional compromise in organs that require 
homeostatic cellular replication, such as the bone marrow, thy-
mus, and endocrine pancreas. Moreover, senescent cells elaborate 
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a host of potent cytokines (which compose the senescence-associ-
ated secretory phenotype [SASP]), and therefore the accumulation 
of senescent cells with aging is also associated with the produc-
tion of proinflammatory factors. Chronic inflammation, whether 
as a consequence of the accumulation of senescent cells or from 
immune dysfunction, is a defining characteristic of mammalian 
aging, is thought to promote several age-related phenotypes, and 
has been dubbed “inflammaging.”
A limited number of interventions for enhancing life span have 
also emerged that are linked to the foregoing core pathways, 
including caloric restriction (CR) and inhibition of the mechanis-
tic TOR (mTOR) pathway. CR clearly results in increased life span 
in a broad array of species, including yeast, C. elegans, flies, and 
rodents. Interestingly, two long-term studies in primates (rhesus 
monkeys) have resulted in different outcomes: one study demon-
strated a benefit of CR on longevity, but the other showed no 
effect; the reasons for this difference are currently unknown but 
are being investigated (2, 3). The benefits of CR for humans have 
been challenged by several large observational studies and a recent 
meta-analysis suggesting that lower BMI in humans is associated 
with increased mortality relative to subjects who are mildly over-
weight (4–6). Critics of this work suggest that BMI is a poor surro-
gate for adiposity and effective CR, but the data seem clear that the 
extreme states of underweight sought by humans attempting CR 
are not associated with reduced mortality on a population basis. 
The precise mechanism by which CR enhances longevity in exper-
imentally housed cohorts of model organisms remains uncertain, 
although CR suppresses TOR and insulin/IGF-1 signaling while 
inducing sirtuin 1 (SIRT1) and other sirtuins. Pharmacologic 
inhibition of TOR — primarily the mTOR complex 1 (mTORC1)— 
with rapamycin and its analogs increases life span in a similarly 
broad array of species as reported for CR. Importantly, the ability 
of CR and TOR inhibition to increase longevity in lower organ-
isms suggests an intrinsic effect of these agents on life span that is 
independent of disease modifiers of longevity. For example, yeast, 
flies, and worms do not develop cancer, indicating that the effects 
of rapamycin to promote longevity are not simply explained by the 
drug’s known antitumor effects. Whether the ability of rapamycin 
to promote longevity in rodents reflects a true anti-aging effect, 
or merely its known anticancer activity, is unsettled. Similarly, in 
model organisms, perturbation of insulin and IGF-1 signaling 
increases longevity independent of disease modifiers.
The Review articles presented here expand upon these core 
concepts, in some cases criticizing underlying assumptions and 
developing a context for gaining deeper understanding. All of the 
articles explore the potential utility of different pathways for ther-
apeutic intervention.
Role of mitochondria
The “free radical hypothesis” of aging described by Harman in 
1956 (7) is perhaps the oldest theory of aging and still has many 
firm adherents. However, as pointed out in the Review by Bratic 
and Larsson in this series (8), and by others (9, 10), the free radical 
hypothesis of aging has become increasingly controversial. What 
is troubling for this model is the reproducible finding that phar-
macologic or genetic neutralization of toxic oxygen radicals or 
augmentation of antioxidant defenses, while sufficient to reduce 
measures of damaging oxidative stress, are often not effective in 
enhancing life span. Furthermore, there is a growing appreciation 
that acute production of ROS has normal and beneficial effects 
on signal transduction, control of gene expression, and other bio-
logical functions, indicating that chronic or complete suppres-
sion of ROS production could be deleterious. Bratic and Larsson 
provide evidence for an alternative pathway of aging-associated 
mitochondrial dysfunction that can lead to functional decline of 
cells independent of ROS production (8). Aging is known to be 
associated with mutations in genes of the mitochondrial genome, 
Figure 1
Molecular pathways implicated in aging. Molecular pathways that drive 
cellular senescence may contribute to aging and age-related diseases 
by disrupting tissue homeostasis through impaired stem cell renewal 
and by promoting the spread of senescence and inducing chronic 
inflammation through the SASP. Reviews in this series highlight sev-
eral of these pathways, including the contribution of telomere dysfunc-
tion to age-associated disease (24), the mTOR signaling pathway and 
mechanisms underlying mTOR inhibitors in increasing longevity (13), 
the role of the sirtuin family of proteins in regulating metabolism and 
aging-associated diseases (16), the role of mitochondrial dysfunction 
in aging, including caveats of the long-held free radical hypothesis of 
aging (8), and the role of cellular senescence and the induction of the 
SASP in systemic aging (23). The SASP may promote increased tissue 
inflammation and dysfunction, which leads to aging phenotypes such 
as the decline in immune system function (26). Aging also decreased 
β cell regeneration in pancreatic islets (25).
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which encodes key proteins of the respiratory complex, including 
components of the electron transport chain and ATP synthase 
complexes. Because the mitochondrial genome replicates inde-
pendently of the nuclear genome, mutations generated during 
replication of the mitochondrial genome can result in uneven dis-
tribution of wild-type and mutated mitochondrial DNA (mtDNA) 
between different cells and tissues. Thus, some cells may have a 
preponderance of mutated mtDNA even when the absolute levels 
of mutated mtDNA are low on an organism-wide basis. This can 
lead to mosaic deficiencies in mitochondrial function among dif-
ferent cells and tissues.
Recent support for this hypothesis has been gained by the devel-
opment of mtDNA mutator mice (11), which lack expression of 
the proofreading enzyme mtDNA polymerase, leading to accel-
erated and extensive mtDNA mutagenesis. These mice develop a 
progeroid, or early-aging syndrome. In contrast, a different mouse 
strain, the mtDNA deletor mouse, expresses a dominant-negative 
version of twinkle, the mtDNA helicase, resulting in accumu-
lation of large-scale deletions in mtDNA in postmitotic tissues 
(12). Although these animals exhibit late-onset mitochondrial 
myopathy and a decline in respiratory function, they have no 
obvious progeroid syndrome, which suggests that accumulation 
of mtDNA mutations and mitochondrial dysfunction are not 
sufficient to accelerate aging. Instead, recent work has suggested 
that the absence of a fully functional pool of somatic stem cells 
contributes to the premature aging phenotype of the mtDNA 
mutator mouse strain (8). While interesting, it remains to be deter-
mined whether accrual of mtDNA mutations contributes to the 
normal aging process, given that the high rate of such mutations 
in murine models will not be matched in terms of timing or fre-
quency in normal human aging.
Rapalogs and TOR
Lamming et al. focus on the TOR pathway in aging and on TOR 
inhibitors as a potential interventional tool (13). The most well-
known TOR inhibitor, rapamycin, has been used in humans for 
many years to inhibit graft rejection in tissue transplant sub-
jects and has garnered recent attention as a potential anticancer 
therapeutic. Interest in rapamycin as an anti-aging drug stems 
from multiple lines of genetic evidence implicating TOR and its 
substrate S6 kinase 1 (S6K1) in aging in yeast, flies, worms, and 
rodents. Rapamycin extends life span in all of these species and 
is thus touted as the most widely tested and efficacious phar-
macotherapy for aging that is currently known. However, the 
mechanisms involved in this effect remain uncertain. mTORC1 
and S6K1 regulate general protein translation via the eukaryotic 
initiation factor eIF4E binding protein (4E-BP). Inhibition of 
mTOR also leads to increased degradation and recycling of pro-
teins via activation of the process of autophagy. Thus, rapamycin 
may reduce cell stress via a dual-edged mechanism for control-
ling cellular protein content, with salutary effects such as reduc-
ing flux of protein through the endoplasmic reticulum. Yet the 
TOR pathway also has life span–extending activity independent 
of S6K1 or translation initiation factors. The possibility remains 
that selective inhibition of the translation of certain transcripts 
may play a key role in the anti-aging effects of rapamycin, a topic 
that is gaining increasing attention. In an interesting conver-
gence with the mtDNA mutation hypothesis, rapamycin has 
potent effects on stem cell function, with the general property of 
promoting self-renewal capacity.
Although rapamycin is used clinically to prevent organ rejection, 
treat renal cell carcinoma, and coat coronary stents, and is being 
tested in various other clinical trials, it is unlikely to be of use 
in increasing longevity in healthy subjects due to its diverse and 
still-emerging side effects. The most prominent among these are 
related to its immunosuppressive activities, including increased 
incidence of viral and fungal infections. Rapamycin also has been 
shown to cause edema, ulcers, rash, and hair and nail disorders, 
as well as a host of metabolic changes reminiscent of metabolic 
syndrome, including hyperlipidemia, insulin resistance, and glu-
cose intolerance. Lamming et al. suggest that some, if not all, of 
these side effects could be averted by development of new forms of 
TOR inhibitors that modestly suppress mTORC1, with no chronic 
effect on mTORC2 (13). Interestingly, the most widely used diabe-
tes drug in the world today, metformin, was recently discovered to 
be an inhibitor of mTORC1, and is capable of decreasing phospho-
rylation of the mTORC1 substrates S6K1 and 4E-BP1 (14). Unlike 
the effects of chronic rapamycin treatment, metformin reverses 
several of the symptoms of metabolic syndrome and is very well 
tolerated over long periods of time in humans. It also increases 
longevity in species ranging from yeast to mice and was even found 
to decrease mortality from all causes in humans in a long-term 
diabetes study (15). The mechanism of action of metformin in 
diabetes treatment is not fully understood. Interestingly, the drug 
decreases the activity of complex I of the electron transport chain, 
and also increases the activity of AMPK. AMPK inhibits mTORC1 
complex activity, providing a link between the rapamycin and met-
formin mechanisms for promoting longevity.
The role of sirtuins in aging
Hall et al. discuss the possible role of the sirtuin family of enzymes 
in the control of aging (16), a field that had its origins with the 
report that overexpression of the yeast sirtuin Sir2 resulted in 
increased life span in that simple organism (17). Since then, the 
field has been remarkably controversial, and some uncertainty 
remains as to the extent to which sirtuins influence fundamen-
tal aging processes, as opposed to control of activities that can 
contribute to life span such as energy metabolism, development 
of cancer, and gene transcription (18, 19). Further complexity 
is introduced by the fact that mammals express 7 sirtuin gene 
family members localized to diverse subcellular compartments, 
with different tissue distribution patterns and still-emerging dif-
ferences in catalytic and biologic functions. Finally, many of the 
claims related to sirtuins and age-related pathologies come from 
studies relying on putative sirtuin activators (e.g., resveratrol), 
but several groups have challenged the pharmacologic effects of 
these agents (20–22). The Review by Hall et al. highlights some of 
the controversies concerning sirtuins and aging, but also focuses 
on the role of each of the sirtuin family members in important 
areas of biology (16). One connection that emerges between sir-
tuins and the core aging process in mammals is the induction 
of several family members in response to CR. Increased expres-
sion of the nuclear sirtuin SIRT1 and the mitochondrial sirtuin 
SIRT3 contributes to metabolic adaptations to CR. SIRT1 cat-
alyzes the deacetylation of the key transcriptional coregulator 
PGC-1α, enhancing its activity and contributing to transcrip-
tional upregulation of multiple genes encoding enzymes of the 
fatty acid β-oxidation pathway. Coinduction of SIRT3 results in 
deacetylation of some of the same enzymes that are upregulated 
by SIRT1/PGC-1α, increasing their enzymatic activity. However, 
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it remains unclear why selective activation of oxidation of fatty 
acids relative to glucose is a strategy to promote longevity. The 
confusion is heightened by studies that show mitigation of met-
abolic dysfunction and insulin resistance in response to either 
overexpression or knockdown of SIRT1. Nevertheless, emerging 
evidence for cardioprotective, antitumoral, and neuroprotective 
effects of the mammalian sirtuins, as summarized in the Review 
by Hall et al. (13), argue that further investigation of the connec-
tions between sirtuins and aging could well be fruitful.
Cellular replication and aging
The series includes four articles that discuss cellular replication 
and aging. Two Reviews focus on the role of cellular senescence 
in aging (23, 24), whereas the others describe the consequences 
of a decline in age-associated tissue regeneration in the endocrine 
pancreas (25) and cellular immune system (26).
“Senescence” in common parlance refers to any functional 
decline with aging, but “cellular senescence” in cell biology refers 
to a specific phenomenon of permanent cellular growth arrest, 
first described by Hayflick and Moorehead in vitro in the 1960s 
(27). Senescent cells (in the Hayflickian sense) exhibit several phe-
notypic features including changes in gene expression and mor-
phology, and remain growth arrested in culture for years or longer. 
Senescent cells cannot generally be coaxed to reenter the cell cycle 
by ordinary means, such as expression of oncogenes or addition 
of mitogens. Several lines of recent evidence have compellingly 
demonstrated that senescent cells accumulate in vivo with aging 
in mammals and that the activation of the senescence program is a 
key component of mammalian anticancer defenses. Therefore, the 
senescence theory of aging holds that this mechanism is antagonis-
tically pleiotropic, preventing cancer in young age, but promoting 
aging in older organisms. The loss of replicative capacity and accu-
mulation of senescent cells is thought to promote aging in at least 
two ways: through the loss of the beneficial, replicative function of 
certain cell types and through the production of proinflammatory 
cytokines (i.e., the SASP). The Reviews by Kushner (25) and the 
Dorshkind group (26) predominantly discuss the consequences of 
reduced replication, while Tchkonia et al. address the age-promot-
ing effects of the SASP (23). The Review by Armanios (24) describes 
the in vivo consequences of telomere dysfunction, which is one of 
the most important organismal mediators of senescence. However, 
it is clear that not all replicative failure with aging results from cel-
lular senescence (also discussed in refs. 25, 26), and it is not gener-
ally known, even for the endocrine pancreas and lymphoid organ, 
to what degree the failure of cellular replication that occurs with 
aging in these tissues is the result of senescence activation versus 
other forms of nonpermanent growth arrest.
Telomeres are complex nucleoprotein structures that serve to 
protect chromosomal ends from activating DNA damage response 
and end-to-end fusions. Telomere length shortens slightly with 
each cell division, and when telomere shortening occurs beyond 
a certain point, telomere dysfunction ensues, which is associated 
with activation of a DNA damage response and the induction of 
cellular senescence. Counteracting the effects of cellular replica-
tion on telomere length is the telomerase holoenzyme complex, 
which is active in germ cells and certain self-renewing somatic 
cells to preserve replicative capacity throughout life. As described 
by Armanios (24), humans and mice lacking normal telomerase 
activity have been shown to exhibit some features of premature 
aging, and in particular, human telomerase deficiency is associated 
with pulmonary fibrosis, bone marrow failure, cirrhosis, and other 
age-associated conditions. The Review by Armanios describes the 
use of telomere-based tests for the diagnosis and management of 
human conditions, as well as the role of therapies aimed at altering 
telomere metabolism to combat certain age-related conditions (24).
Cellular senescence is activated by a number of cellular stresses, 
including telomere dysfunction, with the beneficial effect of 
preventing cancer. In particular, senescence is associated with 
activation of two classic tumor suppressor pathways, p53 and 
p16INK4a-Rb, to induce durable growth arrest. In contrast to cel-
lular quiescence (i.e., reversible growth arrest), senescence is also 
associated with specific global changes in chromatin architecture 
as well as durable changes in gene expression. Importantly, senes-
cent cells become a veritable factory of inflammatory cytokines, 
producing high levels of potent, pleiotropic molecules such as 
IL-6, IL-8, TNF-α, and VEGF-a, with profound effects on local 
inflammation, angiogenesis, fibrosis, and wound healing. Tchko-
nia et al. (23) describe the effects of the SASP in aging mammals, as 
well as the therapeutic potential of reducing the burden of senes-
cent cells as a treatment for aging. This model of senescence and 
aging has particular appeal, as one can envision several approaches 
to counteract the adverse effects of SASP-associated cytokines or 
to clear senescent cells through an immune-mediated approach.
A decline in cellular immunity is one of the most clinically famil-
iar and morbid features of human aging. Montecino-Rodriguez 
et al. (26) carefully describe the features of aging of the various 
components of the cellular immune system including HSCs, thy-
mus, and B and T lymphocytes. HSC function appears to decline 
with aging in the absence of senescence induction, whereas the 
function of lymphoid progenitors may exhibit senescence-depen-
dent replicative failure. The Review discusses important recent 
findings regarding the role of milieu in cellular immune aging, 
summarizing data showing how “inflammaging” and a decline in 
thymic function can both induce an age-related decline in lympho-
cyte function. Additionally, the Review includes a discussion of 
provocative approaches to “rejuvenate” immune aging in humans 
through the use of IL-7 and other factors to counteract the loss in 
thymic function and naive T cell production that occurs with age.
The response of pancreatic islet β cells to aging provides an 
interesting context for describing the contribution of molecu-
lar mechanisms to reduced proliferative and regenerative capac-
ity of tissues over time, as reviewed by Kushner in this series 
(25). The loss of regenerative capacity in β cells that occurs 
with age is relevant because inadequate β cell mass and func-
tion are at the heart of development of both major forms of 
diabetes, and no reliable strategies are currently available to 
reverse this problem. Proliferation of β cells slows markedly 
with age in rodents and humans, and islets from aged rodents 
are poorly responsive to proliferative stimuli such as glucagon-
like peptide 1 and high-fat feeding. In β cells and other tissues, 
aging-related decreases in proliferation are linked to increased 
expression of cyclin-dependent kinase inhibitors (CDKIs). In 
islets, p16INK4a plays a particularly prominent role, as supported 
by several lines of evidence. First, knockout of p16INK4a increases, 
and overexpression of p16INK4a decreases, β cell proliferation 
(28). Second, manipulation of multiple pathways and factors 
that control p16INK4a, including the polycomb proteins BMI1 
and EZH2, and the PDGF and p38 MAPK signaling pathways, 
alter β cell replication in rodent models of aging in a p16INK4a- 
associated fashion. One recent study demonstrated that islets 
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from aged rodents and humans have reduced expression of the 
PDGFR (29). Restoration of PDGFR expression in older mice 
enhanced β cell proliferation via induction of the p16INK4a sup-
pressive factor EZH2. Despite these advances in understand-
ing age-related changes in control of the cell cycle in islet cells, 
no methods have yet been reported to induce proliferation of 
human islet β cells from older donors in vitro. Interestingly, 
there is one report showing that transplantation of pancreatic 
islets into young but not old mice enables β cell proliferation 
in islets from older rodent or human donors (30). These find-
ings implicate a factor or factors present in young mice that can 
activate proliferation in otherwise quiescent islets from aged 
donors. Further studies will be required to identify such puta-
tive factors and to test their utility for expansion of functional 
islet cell mass in post-adolescent diabetic patients.
Summary and conclusions
This collection of Reviews reinforces the view that our basic under-
standing of the cellular and molecular biology of aging is begin-
ning to lead to therapies to address this fundamental process in 
humans. Novel aging diagnostics related to telomeres and other 
markers of senescence are being validated for use in certain clinical 
scenarios. Human trials of agents including metformin, rapalogs, 
PDGF, and IL-7, thought to counter aging and aging sequelae, are 
being planned or are already started. Molecular events associated 
with CR and anabolic signaling are increasingly understood and 
may eventually become anti-aging targets. These Reviews suggest 
even more definitive (and presently more theoretical) approaches 
such as the generation of replacement cells using induced pluripo-
tent stem cell technology or stimulating immune clearance of 
damaged or senescent cells through a vaccination approach. While 
still in the conception stage, such ideas are supported by preclin-
ical efficacy studies in rodents and, we believe, have the potential 
to change the arc of physiological aging in humans in our lifetime.
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